Detection and Extraction of Heparin from Camel Lungs
-
Published:2019-07-09
Issue:6
Volume:20
Page:476-482
-
ISSN:1389-2010
-
Container-title:Current Pharmaceutical Biotechnology
-
language:en
-
Short-container-title:CPB
Author:
Almeman Ahmad1, Abdulmajed Kasem2, Eid Eltayeb E.2
Affiliation:
1. Clinical Pharmacology and Therapeutic Department, Medicine Faculty, Qassim University, Almulaida, Saudi Arabia 2. Medical Sciences Department, Faculty Medicine Unyzah Campus, Qassim University, Unyzah, Saudi Arabia
Abstract
Background:
Heparin is an essential drug used as an anticoagulant. Access to raw material
suitable for heparin extraction is critical for creating a viable business opportunity. In Saudi Arabia,
large amounts of raw material with potential for heparin extraction are wasted.
Objective:
To extract heparin and low-molecular-weight heparin (LMWH) from the camel lung, and
measure its potency and activity.
Methods:
Heparin preparation included three steps: extraction, electrophoretic identification, and activity
measurement. Fresh lung tissue (100 g) was minced and homogenized in a blender. Crude heparin
extracts were prepared using Charles’s or Volpi’s method with slight modifications. Heparin was purified
by electrophoresis using high-purity agarose gels in barium acetate buffer. The heparin activity of
purified samples was assayed spectrophotometrically using commercial heparin kits.
Results:
Charles’s and Volpi’s extraction methods were simple and easy to establish. The yield was 90
mg crude heparin per 100 g of camel lung tissue following Volpi’s extraction protocol, whereas
Charles’s method did not yield any heparin. The separation of heparin and LMWH by gel electrophoresis
resulted in sharp and clear product bands using material prepared according to Volpi’s method.
The heparin preparation had an anti-factor Xa activity of 37 IU/mg, indicating weak potency.
Conclusion:
Preparation of active heparin from camel lung tissue is a technology applicable in manufacturing.
Further method development is needed to increase heparin purity and potency.
Funder
Qassim University, Deanship for Scientific Research, Saudi Arabia
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Reference29 articles.
1. . , WHO Model List of Essential Medicines (19th List). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016,, , ,, -, 2. Hylek EM, Regan S, Henault LE, Gardner M, Chan AT, Singer DE, Barry MJ. Arch Intern Med, Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.,, 2003, 163,, 621-627, 3. Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, McBane RD, Moll S, Ansell J. J Thromb, Guidance for the treatment of deep vein thrombosis and pulmonary embolism.,, 2016, 41,, 32-67, 4. Li JJ, Corey EJ. Drug discovery: Practices, Processes, and Perspectives, ,, 2013, 41,, 32-, 5. . Drug discovery: Practices, Processes, and Perspectives, ,, , 41,, 32-,United States Food and Drug Administration (2010) Generic enoxaparin questions and answers. Accessed 15 Jan 2019.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|